ANIK Anika Therapeutics, Inc.

Nasdaq anikatherapeutics.com


$ 9.17 $ 0.08 (0.88 %)    

Friday, 17-Oct-2025 15:59:57 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 9.17
$ 8.98
$ 8.85 x 2
$ 9.44 x 70
$ 8.67 - $ 9.17
$ 7.87 - $ 25.44
125,648
na
132.21M
$ 0.87
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-30-2025 06-30-2025 10-Q
2 05-09-2025 03-31-2025 10-Q
3 03-14-2025 12-31-2024 10-K
4 11-04-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 03-15-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-16-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 03-11-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-07-2021 03-31-2021 10-Q
19 03-05-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-07-2020 06-30-2020 10-Q
22 05-22-2020 03-31-2020 10-Q
23 03-06-2020 12-31-2019 10-K
24 10-28-2019 09-30-2019 10-Q
25 07-26-2019 06-30-2019 10-Q
26 05-06-2019 03-31-2019 10-Q
27 02-27-2019 12-31-2018 10-K
28 10-26-2018 09-30-2018 10-Q
29 07-31-2018 06-30-2018 10-Q
30 05-10-2018 03-31-2018 10-Q
31 02-27-2018 12-31-2017 10-K
32 10-27-2017 09-30-2017 10-Q
33 07-28-2017 06-30-2017 10-Q
34 05-04-2017 03-31-2017 10-Q
35 02-24-2017 12-31-2016 10-K
36 11-01-2016 09-30-2016 10-Q
37 08-01-2016 06-30-2016 10-Q
38 05-03-2016 03-31-2016 10-Q
39 03-10-2016 12-31-2015 10-K
40 11-03-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 barrington-research-maintains-outperform-on-anika-therapeutics-maintains-15-price-target

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and maintains $15 p...

 barrington-research-maintains-outperform-on-anika-therapeutics-lowers-price-target-to-15

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and lowers the pric...

 anika-therapeutics-q2-adj-eps-013-beats-017-estimate-sales-2822m-beat-2770m-estimate

Anika Therapeutics (NASDAQ:ANIK) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(...

 anika-therapeutics-topline-results-from-its-us-pivotal-trial-of-hyalofast-for-articular-knee-cartilage-defect-lesions-demonstrated-improvements-over-microfracture-but-missed-on-statistical-significance-of-the-pre-specified-co-primary-endpoints

Hyalofast consistently demonstrated improvements over microfracture, but missed on statistical significance of the pre-specifie...

 barrington-research-maintains-outperform-on-anika-therapeutics-lowers-price-target-to-19

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and lowers the pric...

 barrington-research-maintains-outperform-on-anika-therapeutics-lowers-price-target-to-20

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and lowers the pric...

 us-stocks-likely-to-open-lower-after-a-brief-respite-add-exposure-to-equities-amid-pullback-says-expert

U.S. stock futures fell again on Thursday after a brief respite on Wednesday, following a softer-than-expected inflation print.

 barrington-research-maintains-outperform-on-anika-therapeutics-lowers-price-target-to-25

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and lowers the pric...

 anika-closes-divestiture-of-its-arthrosurface-business-and-intention-to-divest-of-parcus-medical-business

The sale of the Company's Arthrosurface business to Phoenix Brio, Incorporated closed today, October 31, 2024. The Company ...

 anika-therapeutics-q3-2024-adj-eps-025-misses-001-estimate-sales-3875m-miss-4208m-estimate

Anika Therapeutics (NASDAQ:ANIK) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION